Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-04-16
2009-10-06
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07598227
ABSTRACT:
Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5877009 (1999-03-01), Zannis et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6010849 (2000-01-01), Edwards et al.
patent: 6184212 (2001-02-01), Miraglia et al.
patent: 6300132 (2001-10-01), Monia et al.
patent: 6500672 (2002-12-01), Sladek et al.
patent: 6852536 (2005-02-01), Dobie
patent: 2004/0208856 (2004-10-01), Crooke et al.
patent: WO 03/011887 (2003-02-01), None
Opalinska et al. Nucleic acid therapeutics: Basic principles and recent applications. Nature Review, 2002, vol. 1, pp. 503-514.
Jen et al. Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies. Stem Cells 2000, vol. 18, pp. 307-319.
Crooke, S.T. Progress in antisense technology 2004 Annu. Rev. Med. vol. 55, pp. 61-95.
Webster's II New Riverside University Dictionary 1994 The Riverside Publishing Company. pp. 933 & 944.
Oliveri et al. Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and insulin resistant T-455C APOC3 gene polymorphism in heard disease patients: Example of gene-diet interaction.
Braasch, D. A. Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry. Apr. 2002; 41(14): 4503-4510.
Branch, A. D. A good antisense molecule is hard to find. Trends Biochem Sci. Feb. 1998;23(2):45-50.
Gewirtz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. 1996. v 93, pp. 3161-3163.
Tamm, I. et al. Antisense therapy in oncology: new hope for an old idea. The Lancet. Aug. 2001, 358: 489-497.
Agrawal et al. Antisense therapeutics: is it as simple as complementary base recognition? Molecular Medicine Today, vol. 6, p. 72-81, Feb. 2000.
Senior, K. Antisense inhibitor provides new treatment approach for hypercholesterolaemia. Drug Discovery Today, 2002 vol. 7:840-841.
Dammerman et al.,An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms, Proc. Natl. Acad. Sci. U. S. A.,1993, 90:4562-4566.
de Silva et al.,Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E, J. Biol. Chem.,1994, 269:2324-2335.
Hertz et al.,Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III, J. Biol. Chem.,1995, 270:13470-13475.
Ito et al.,Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice, Science, 1990, 249:790-793.
Karathanasis,Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII, and AIV genes, Proc. Natl. Acad. Sci. U. S. A.,1985, 82:6374-6378.
Kardassis et al.,Direct physical interactions between HNF-4 and Sp1 mediate synergistic transactivation of the apolipoprotein CIII promoter, Biochemistry, 2002, 41:1217-1228.
Kardassis et al.,SMAD proteins transactivate the human ApoCIII promoter by interacting physically and functionally with hepatocyte nuclear factor 4, J. Biol. Chem.,2000, 275:41405-41414.
Levy-Wilson et al.,Isolation and DNA sequence of full-length cDNA for human preapolipoprotein CIII, DNA, 1984, 3:359-364.
Li et al.,Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia, J. Clin. Invest.,1995, 96:2601-2605.
Maeda et al.,Molecular cloning of a human apoC-III variant: Thr 74—Ala 74 mutation prevents O-glycosylation, J. Lipid Res.,1987, 28:1405-1409.
Maeda et al.,Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia, J. Biol. Chem.,1994, 269:23610-23616.
Ogami et al.,Purification and characterization of a heat stable nuclear factor CIIIB1 involved in the regulation of the human ApoC-III gene, J. Biol. Chem.,1991, 266:9640-9646.
Olivieri et al.,ApoC-III gene polymorphisms and risk of coronary artery disease, J. Lipid Res.,2002, 43:1450-1457.
Protter et al.,Isolation and sequence analysis of the human apolipoprotein CIII gene and the intergenic region between the apo AI and apo CIII genes, DNA, 1984, 3:449-456.
Raspe et al.,Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription, J. Lipid Res.,2002, 43:2172-2179.
Schoonjans et al.,3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase, FEBS Lett.,1999, 452:160-164.
Shachter,Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism, Curr. Opin. Lipidol.,2001, 12:297-304.
Sharpe et al.,Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA abundance, Nucleic Acids Res, 1984, 12:3917-3932.
Vu-Dac et al.,Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids, J. Clin. Invest.,1998, 102:625-632.
International Search Report and Written Opinion from PCT/US04/10946 dated Feb. 22, 2006.
Chan et al., “Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration” Metabolism Clinical and Experimental (2002) 51(8):1041-1046.
Crooke, “Antisense oligonucleotides as therapeutics for hyperlipidaemias” Expert Opinion on Biological Therapy (2005) 5(7):907-917.
Jong et al., “Role of ApoCs in Lipoprotein Metabolism - Functional Differences Between ApoC1, ApoC2, and ApoC3” Arterioscler. Thromb. Vase. Biol. (1999) 19:472-484.
Jover et al., “Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting” Hepatology (2001) 33(3):668-675.
Klein et al., “P2841 Apoprotein C-III (ApoCIII) Protein Concentrations and Gene Polymorphisms in Type 1 Diabetes” Aretioseler. Thromb. Vase. Biol. (2002) 22(5):A-50.
Nielsen, “Systemic Delivery: The Last Hurdle?” Gene Therapy (2005) 121956-957.
Supplementary European Search Report for EP 04749914.0 dated Jan. 5, 2009.
Crooke Rosanne M.
Dobie Kenneth W.
Graham Mark J.
Lemonidis Kristina M.
Gibbs Terra Cotta
Isis Pharmaceuticals , Inc.
Jones Day
McGarry Sean
LandOfFree
Modulation of apolipoprotein C-III expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of apolipoprotein C-III expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of apolipoprotein C-III expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4095670